News AZ is three for three with COPD hope tozorakimab AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.
Digital From static documents to strategic capability: The case for ... Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.
News UK says it has hit target on commercial trial set-up times The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.
News Lilly says Foundayo safety confirmed in ACHIEVE-4 trial Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.
News Most patients "won't see benefit" with Alzheimer's drugs A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.
News FDA renews criticism of trial sponsors over transparency The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.